Literature DB >> 26407652

The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.

Yvonne Reinke1, Stefan Gross1, Lars G Eckerle2, Isabel Hertrich2, Mathias Busch2, Raila Busch1, Alexander Riad1, Bernhard H Rauch3, Johannes-Peter Stasch4, Marcus Dörr1, Stephan B Felix5.   

Abstract

In cardiovascular diseases, reduced responsiveness of soluble guanylate cyclase (sGC) to nitric oxide (NO) upon long-term application has led to the development of NO-independent sGC stimulators (heme-dependent) and sGC activators (heme-independent). Any direct inotropic or lusitropic effects of these compounds on isolated cardiac myocytes, however, remain to be elucidated. Here, we analyzed the dose-dependent effects of clinical relevant concentrations (10(-10)-10(-5) M) of the sGC activator cinaciguat and the sGC stimulator riociguat on the contraction, relaxation, and calcium transients of isolated field-stimulated cardiac myocytes from healthy rats. For comparison, we used isoproterenol, which induced a dose-dependent significant increase in cell contractility, relaxation, and calcium transients, verapamil that significantly decreased these parameters (both at 10(-9)-10(-5) M) and 8-(4-Chlorophenylthio)-guanosine 3',5'-cyclic monophosphate (8-pCPT-cGMP) that induced a negative inotropic effect at 10(-5) M accompanied by a slight increase in relaxation. In contrast, neither cinaciguat nor riociguat significantly influenced any measured parameters. Furthermore, isoproterenol significantly increased intracellular cAMP levels that were not influenced by cinaciguat or riociguat (all at 10(-6) M). Otherwise, riociguat and cinaciguat (both at 10(-6) M) significantly enhanced intracellular cGMP generation. This accumulation was significantly augmented by cinaciguat in the presence of the sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 25 µM), whereas ODQ blocked cGMP generation by riociguat. However, blocking of sGC did not influence cell contractility. Our results demonstrate that, in isolated cardiac myocytes from healthy rats, the increase in cGMP levels induced by cinaciguat and riociguat at clinical relevant concentrations is not associated with acute direct effects on cell contraction and relaxation.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  8-(4-Chlorophenylthio)-guanosine3′,5′-cyclic monophosphate sodium salt (8-pCPT–cGMP) (PubChem CID: 23679064); Cell contraction; Cell relaxation; Cinaciguat; Cinaciguat (PubChem CID: 9808022); H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (PubChem CID: 1456); Isoproterenol (PubChem CID: 3779); Rat cardiac myocytes; Riociguat; Riociguat (PubChem CID: 11304743); Verapamil (PubChem CID: 62969); cGMP

Mesh:

Substances:

Year:  2015        PMID: 26407652     DOI: 10.1016/j.ejphar.2015.09.022

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways.

Authors:  Kaiqiang Sun; Fanqi Kong; Feng Lin; Fudong Li; Jingchuan Sun; Changzhen Ren; Bing Zheng; Jiangang Shi
Journal:  Mediators Inflamm       Date:  2022-06-16       Impact factor: 4.529

Review 2.  Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?

Authors:  Cody Koress; Kevin Swan; Philip Kadowitz
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

3.  Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts.

Authors:  Lukas Menges; Christian Krawutschke; Ernst-Martin Füchtbauer; Annette Füchtbauer; Peter Sandner; Doris Koesling; Michael Russwurm
Journal:  Br J Pharmacol       Date:  2019-12-27       Impact factor: 8.739

4.  Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.

Authors:  Torvind Næsheim; Ole-Jakob How; Truls Myrmel
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-07-14       Impact factor: 2.457

5.  Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021.

Authors:  Xiao-Yan Jia; Yong-Ming Liu; Yong-Fei Wang; Jin-Yang An; Ke-Ling Peng; Hua Wang
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

Review 6.  Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Authors:  Wolfgang Kreisel; Denise Schaffner; Adhara Lazaro; Jonel Trebicka; Irmgard Merfort; Annette Schmitt-Graeff; Peter Deibert
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.